Gilead to unblind Zydelig trial on early CLL efficacy

Gilead Sciences Inc. (NASDAQ:GILD) said an interim analysis by an independent data monitoring committee showed Zydelig idelalisib plus standard therapy improved progression-free survival (PFS), the study's primary endpoint, vs. standard therapy alone in a Phase III trial in previously treated chronic lymphocytic leukemia (CLL). Gilead said it will unblind the trial early.

Zydelig plus Treanda bendamustine and Rituxan rituximab also led to a statistically significant overall survival (OS) benefit. Data will be presented at the American Society of Hematology meeting in December. ...